{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:02:16Z","timestamp":1772744536500,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.tranon.2022.101418","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T18:17:24Z","timestamp":1649873844000},"page":"101418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5592","authenticated-orcid":false,"given":"Remziye","family":"Zaim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-4083","authenticated-orcid":false,"given":"Ken","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5808-302X","authenticated-orcid":false,"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2022.101418_bib0001","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2022.101418_bib0002","series-title":"The US Food and Drug Administration: OPDIVO (nivolumab)","year":"2022"},{"key":"10.1016\/j.tranon.2022.101418_bib0003","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2022.101418_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2022.101418_bib0005","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2022.101418_bib0006","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0007","series-title":"List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)","year":"2022"},{"key":"10.1016\/j.tranon.2022.101418_bib0008","series-title":"21st Century Cures Act. H.R.34 \u2014 114th Congress (2015-2016)","year":"2022"},{"key":"10.1016\/j.tranon.2022.101418_bib0009","series-title":"CDER Patient-Focused Drug Development","year":"2022"},{"key":"10.1016\/j.tranon.2022.101418_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.tranon.2022.101418_bib0011","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0012","article-title":"Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: a Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2022.101418_bib0014","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X","article-title":"Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale","volume":"73","author":"Hollen","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.tranon.2022.101418_bib0016","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.tranon.2022.101418_bib0017","article-title":"Guide to methods of technology appraisal","year":"2013","journal-title":"Process Methods"},{"key":"10.1016\/j.tranon.2022.101418_bib0018","series-title":"2020-2023 Value Assessment Framework","year":"2020"},{"key":"10.1016\/j.tranon.2022.101418_bib0019","series-title":"Value Assessment Methods and Pricing Recommendations For Potential cures: A technical Brief","article-title":"Institute for clinical and economic review","author":"Chapman","year":"2019"},{"key":"10.1016\/j.tranon.2022.101418_bib0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the european society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0021","unstructured":"European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man the use of patient-reported outcome (PRO) measures in oncology studies. EMA\/CHMP\/292464\/2014. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf (accessed 2 Jan 2022)."},{"key":"10.1016\/j.tranon.2022.101418_bib0022","series-title":"Guidance For Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.tranon.2022.101418_bib0023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Pol. (New York)"},{"key":"10.1016\/j.tranon.2022.101418_bib0024","series-title":"EQ-5D-3 L User guide. Version 6.0","year":"2018"},{"key":"10.1016\/j.tranon.2022.101418_bib0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000244","article-title":"An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients","volume":"9","author":"Gralla","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0026","series-title":"Self-Reported Population Health: An International Perspective based On EQ-5D","year":"2014"},{"key":"10.1016\/j.tranon.2022.101418_bib0027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.tranon.2022.101418_bib0028","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.tranon.2022.101418_bib0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the european organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the european organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0031","doi-asserted-by":"crossref","first-page":"S1187","DOI":"10.1016\/j.annonc.2020.08.2292","article-title":"LBA59 first-line nivolumab (NIVO)\u00a0+\u00a0ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): patient-reported outcomes (PROs) from checkmate 9LA","volume":"31","author":"Reck","year":"2020","journal-title":"Annals Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0032","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jtho.2020.12.019","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC With 1% or greater tumor PD-L1 expression: patient-reported outcomes from checkmate 227 part 1","volume":"16","author":"Reck","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.05.005","article-title":"Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057","volume":"102","author":"Reck","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0034","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the checkmate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0036","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1524-4733.2006.00108.x","article-title":"Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population","volume":"9","author":"Bharmal","year":"2006","journal-title":"Value Heal."},{"key":"10.1016\/j.tranon.2022.101418_bib0037","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jtho.2021.02.014","article-title":"Patient-reported outcomes in the era of immunotherapy trials","volume":"16","author":"Gadgeel","year":"2021","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0038","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/jnci\/djaa174","article-title":"Patient-reported outcomes in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2018: a systematic review","volume":"113","author":"Safa","year":"2021","journal-title":"JNCI: J. National Cancer Inst."},{"key":"10.1016\/j.tranon.2022.101418_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227344","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: a systematic review on reporting of methods in randomized controlled trials","volume":"15","author":"Faury","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101418_bib0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaoncol.2016.3328","article-title":"Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials","volume":"3","author":"Atkinson","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0041","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2015.63.6480","article-title":"Patient-reported outcomes labeling for products approved by the office of hematology and oncology products of the US food and drug administration (2010-2014)","volume":"34","author":"Gnanasakthy","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0042","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/cncr.32692","article-title":"Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs","volume":"126","author":"Hansen","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0043","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/PO.20.00164","article-title":"Insights for quantifying the long-term benefit of immunotherapy using quantile regression","author":"Mboup","year":"2021","journal-title":"JCO Precision Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0044","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","article-title":"Do immune checkpoint inhibitors need new studies methodology?","volume":"10","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.tranon.2022.101418_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101418_bib0046","first-page":"djab171","article-title":"Meta-analysis of quality of life in cancer patients treated with immune checkpoint inhibitors","author":"Gonzalez","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2022.101418_bib0047","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1200\/JCO.2009.23.7420","article-title":"Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801","volume":"27","author":"Movsas","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0048","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tranon.2022.101418_bib0050","doi-asserted-by":"crossref","first-page":"djv216","DOI":"10.1093\/jnci\/djv216","article-title":"The imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2022.101418_bib0051","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdy204","article-title":"Reporting of HRQoL results from the PALOMA-2 trial: relevant data are still missing","volume":"29","author":"Kaiser","year":"2018","journal-title":"Annals Oncol."},{"key":"10.1016\/j.tranon.2022.101418_bib0052","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101418_bib0053","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jval.2021.04.1279","article-title":"Patient-reported outcomes after treatment discontinuation: commercial clinical trial data from four cancer types","volume":"24","author":"King-Kallimanis","year":"2021","journal-title":"Value Heal."},{"key":"10.1016\/j.tranon.2022.101418_bib0054","article-title":"Core patient-reported outcomes in cancer clinical trials guidance for industry","year":"2021","journal-title":"Draft Guidance"},{"key":"10.1016\/j.tranon.2022.101418_bib0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332200078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332200078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:21:45Z","timestamp":1761844905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332200078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":55,"alternative-id":["S193652332200078X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101418","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101418"}}